BioNTech SE (NASDAQ:BNTX) Given Average Recommendation of "Moderate Buy" by Brokerages

BioNTech SE (NASDAQ:BNTX - Get Free Report) has received an average rating of "Moderate Buy" from the eighteen analysts that are covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $138.25.

Several equities analysts recently weighed in on the stock. Leerink Partners set a $112.00 price target on shares of BioNTech in a report on Monday, June 2nd. The Goldman Sachs Group initiated coverage on shares of BioNTech in a research note on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective on the stock. Morgan Stanley decreased their target price on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. BMO Capital Markets upped their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th.

Institutional Trading of BioNTech

Institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC purchased a new position in BioNTech in the 1st quarter valued at about $167,000. Millennium Management LLC raised its holdings in shares of BioNTech by 252.5% during the first quarter. Millennium Management LLC now owns 544,970 shares of the company's stock valued at $49,625,000 after acquiring an additional 390,360 shares during the last quarter. Banque Transatlantique SA purchased a new position in shares of BioNTech in the first quarter valued at approximately $80,000. Alyeska Investment Group L.P. boosted its stake in shares of BioNTech by 2,769.2% in the first quarter. Alyeska Investment Group L.P. now owns 75,000 shares of the company's stock worth $6,830,000 after acquiring an additional 72,386 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of BioNTech in the first quarter worth approximately $455,000. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Up 1.6%

Shares of BNTX stock opened at $106.57 on Friday. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm has a market capitalization of $25.62 billion, a PE ratio of -50.75 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock's 50-day simple moving average is $100.98 and its 200-day simple moving average is $108.06.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.